NIPRO CORP.

Research NIPRO CORP. (5FA) on Bullrun: valuation model: 2.2% overvalued, market cap EUR 1.40B, P/E 21.5, dividend yield 2.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker5FA
• ExchangeF
• CountryJapan
• SectorHealthcare
• IndustryMedical Instruments & Supplies
• CurrencyEUR
• Valuation signal2.2% overvalued
• Market capEUR 1.40B
• P/E21.5
• Dividend yield2.0%
• Financial periodFY2025
• RevenueEUR 644.59B
• Revenue growth9.9%
• Net incomeEUR 5.11B
• Free cash flowEUR 68.46B
• Gross margin29.6%

Valuation Snapshot

Bullrun's latest valuation model marks NIPRO CORP. as 2.2% overvalued; latest market cap is EUR 1.40B; P/E is 21.5; dividend yield is 2.0%.

About NIPRO CORP.

Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ-related products, functional products, dialysis products, cell cultures, hospital products, diabetic products, and pharmaceuticals comprising generic and kit products; and manufactures medical equipment, including dialysis medical device products;

Frequently asked questions

Is NIPRO CORP. overvalued or undervalued?

Bullrun's valuation model currently marks NIPRO CORP. as 2.2% overvalued.

What is NIPRO CORP.'s market cap?

NIPRO CORP.'s market capitalization is EUR 1.40B.

What is NIPRO CORP.'s P/E ratio?

NIPRO CORP.'s price-to-earnings (P/E) ratio is 21.5.

Does NIPRO CORP. pay a dividend?

NIPRO CORP. has a dividend yield of 2.0%.

What does NIPRO CORP. do?

Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses.